Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.6.1.2 (alanine aminotransferase)
 26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Mismatched polymerase chain reaction (MPCR) and restriction fragment length polymorphism assay(RFLP) were performed to detect the HBV DNA pre core A83 mutation in 97 patients with chronic HBV infection in Hunan. HBV DNA pre core A83 mutation were detected in 37 out of 97 patients (37/97,38.1%). It was found that the prevalence of HBV DNA pre core A83 mutation of the patients with severe hepatitis and with CAH(chronic active hepatitis) were significantly higher than those with CPH(chronic persistent hepatitis) and carriers of HBV, and the patients with elevated transaminase (ALT > 70U) or positive HBeAb were significantly higher than those with normal transaminase (ALT < 70U) and with positive HBeAg, respectively. The results suggest that the HBV DNA pre core A83 mutation is associated with active and severe liver tissue in patients with hepatitis B.
 ...
PMID:[A study on HBV DNA pre C region A83 mutation in patients with hepatitis B]. 1068 56

The main an etiological agents of chronic hepatitis are viral infections. The viral infection course and outcome depend mostly on the immunological response. Infected hepatocytes are damaged by appropriately viral antigen-specific cytolytic T lymphocytes. Those sensitised T cells react only with those hepatocytes which express viral antigen and antigen HLA on membrane surface. The aim of this study was to evaluate the expression of selected histocompatibility antigens HLA in liver biopsy specimens of patients with chronic viral hepatitis. Seventeen patients with chronic persistent hepatitis (inflammatory activity 1-4 points according to Scheuer scale modified by Gabriel) and 27 patients with chronic active hepatitis (5-10 points) were studied. In these groups of patients the intensity of HLA-I (A, B, C), HLA-II (DR) expression in liver biopsy specimens, alanine aminotransferase activity, markers of HBV and HCV in serum were examined. The monoclonal mouse anti-human antibodies and streptavidin-biotin with alkaline phosphatase method for estimation of HLA-I, HLA-II was used. Results were statistically analysed using Mann-Whitney's U test and Spearman's rank correlation test. Generally, the expression of HLA-I and HLA-II on hepatocyte membrane was shown. Significant differences in expression of HLA-II among studied groups were observed, moreover the highest degree of HLA-II intensity in the group of patients with greater inflammation activity was significantly more frequently observed. The expression of HLA-I, HLA-II was regardless of the viral a etiology and serological markers of HBV replication. The degree of studied parameters expression was positively correlated with biochemical activity of inflammation.
 ...
PMID:[The HLA-I and HLA-II expression evaluation in liver biopsy specimens of patients with chronic viral hepatitis]. 1080 May 78

We report a case of multicentric hepatocellular carcinoma that developed in a 74-year-old man 3 and 6 years after interferon (IFN) treatment for chronic hepatitis C, despite sustained virologic, biochemical, and histological improvement. Initially, serum hepatitis C virus RNA was positive and the patients' serum level of alanine aminotransferase (ALT; 82 IU/ml) was abnormal. Hepatitis B virus (HBV) in the serum was negative for surface antigen, surface antibody, core antibody, and DNA. The patient was started on 10 x 10(6) international units (IU) of IFNalpha, 3 days a week for a total of 24 weeks. After the IFN therapy, the patient demonstrated a normal serum ALT level, and was continuously negative for HCV-RNA, and histology improved from chronic active hepatitis to chronic persistent hepatitis. Follow-up studies with ultrasonography (US) every 3 months and computed tomography (CT) every 6 months revealed no space-occupying lesion (SOL) for 3 years after IFN treatment.US-guided biopsies of two 15-mm hypoechoic SOLs in segments eight (S8) and seven (S7) 34 and 74 months, respectively, after IFN treatment showed well-differentiated hepatocellular carcinoma (HCC). Clinical data, imaging studies, and histologic examinations showed that both tumors were multicentric HCC. Further studies may provide insights into the possible role of HCV in hepatocarcinogenesis in patients demonstrating HCV eradication by IFN treatment.
 ...
PMID:Development of multicentric hepatocellular carcinoma after completion of interferon therapy. 1220 85

Intracellular protein molecules are detected in the blood following release from damaged cells. PDCD5 is widely expressed in most types of normal human tissue and is unregulated in cells undergoing apoptosis. It is therefore hypothesized that release of PDCD5 into the circulation might be a specific marker of apoptosis. In this study, a sandwich ELISA was developed for quantification of soluble PDCD5 protein and used to investigate serum PDCD5 levels in liver diseases. The highest levels of PDCD5 were detected in acute icteric hepatitis (AIH) patients compared with normal subjects and other detected liver diseases, such as chronic active hepatitis B (CAHB), chronic persistent hepatitis B (CPHB) and and liver cirrhosis (LC). Increased PDCD5 levels correlated well with ALT and AST in AIH and CAHB patients. In patients with CPHB, increased PDCD5 levels correlated well with AST, TBI, DBIL, and IBIL. In LC patients, PDCD5 levels correlated well with AST/ALT and DBIL. More importantly, increased PDCD5 levels were also observed in patients with normal ALT or AST levels. These data demonstrate a correlation between increased levels of PDCD5 in serum and liver disease progression and indicate the potential utility of serum PDCD5 as a biomarker for monitoring liver injury.
 ...
PMID:Serum programmed cell death protein 5 (PDCD5) levels is upregulated in liver diseases. 2365 49


<< Previous 1 2 3 4 5 6 7 8 9 10